Peter Greenleaf

Peter Greenleaf

Presidente presso
Maryland Venture Fund

Patrimonio netto: 29 M $ in data 31/05/2026

56 anni
Health Technology
Finance
Commercial Services

Profilo

Peter S.
Greenleaf
is Chairman at Maryland Venture Fund, Chairman at Pelthos Therapeutics, Inc., Chairman at Revolo Biotherapeutics Ltd. since 2020, and holds an Advisory role at Petrichor Healthcare Capital Management LP.
Former roles include President, Chief Executive Officer & Director at Histogenics Corp.
(2013–2014); Chairman & Chief Executive Officer at Sucampo Pharmaceuticals LLC (2016–2018);.
President, Chief Executive Officer & Director at Aurinia Pharmaceuticals, Inc. (2019–2026); Chairman at BioDelivery Sciences International, Inc. (2018–2022); Independent Director at Antares Pharma, Inc. (2018–2022); Independent Director at Mast Therapeutics, Inc.; Director at Oldtech, Inc.; Director at Kiora Pharmaceuticals, Inc. (2018–2020); Director at Biotechnology Innovation Organization; Director at Melinta Subsidiary Corp.; Director at Tech Council of Maryland, Inc.; Director at LigoCyte Pharmaceuticals, Inc.; Independent Director at Mirna Therapeutics, Inc.; Director at Corridor Pharmaceuticals, Inc.; Director at Savara, Inc.; Director at OS Therapies, Inc.; Director at Avalo Therapeutics, Inc. (2019–2020); Director at Pharmaceutical Research & Manufacturers of America; Director at ValenzaBio, Inc.; Senior Vice President-Remicade Franchise at Centocor, Inc. (1998–2006); President at MedImmune LLC (2006–2013); Principal at US Healthcare, Inc.; Principal at Hallmark Cards, Inc.; President at MedImmune Ventures, Inc. (2010–2013); Principal at Roche Diagnostics Corp.
(1996–1998); Trustee at The University of Maryland Baltimore Foundation, Inc.; District Manager at Boehringer Mannheim GmbH (1996–1998); President at AstraZeneca PLC (2006–2013).
Education includes an MBA from St. Joseph's University and undergraduate studies at Western Connecticut State University.

Partecipazioni note in società pubbliche

SocietàDataNumero di azioniValutazioneData di valutazione
02/03/2026 1.840.379 ( 1,43% ) 28 M $ 31/05/2026
0,71%
02/04/2026 24.681 ( 0,71% ) 653 306 $ 31/05/2026

Ultime notizie su Peter Greenleaf

Posizioni attive di Peter Greenleaf

SocietàPosizioneInizio
Presidente -
Presidente 17/12/2020
Consulente / Consigliere -

Precedenti posizioni note di Peter Greenleaf

SocietàPosizioneFine
AURINIA PHARMACEUTICALS INC. Amministratore Delegato 23/03/2026
ANTARES PHARMA, INC. Direttore/Membro del Consiglio 24/05/2022
BIODELIVERY SCIENCES INTERNATIONAL, INC. Presidente 22/03/2022
AVALO THERAPEUTICS, INC. Amministratore Delegato 15/04/2019
KIORA PHARMACEUTICALS, INC. Direttore/Membro del Consiglio 03/01/2020
Vedi nel dettaglio l'esperienza di Peter Greenleaf

Formazione di Peter Greenleaf

Esperienze
Posizioni ricoperte

Attive

Inattive

Società nel listino

Aziende private

Relazioni

69

Relazioni di 1° grado

33

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Società collegate

Aziende private33

Health Technology

Health Technology

Health Services

Health Technology

Health Technology

Health Technology

Consumer Non-Durables

Health Technology

Health Technology

Finance

Health Technology

Health Technology

Commercial Services

Health Technology

Consumer Services

Consumer Services

Health Technology

Health Technology

Commercial Services

Health Technology

Health Technology

Miscellaneous

Finance

Commercial Services

Health Technology

Health Technology

Health Technology

Boehringer Mannheim GmbH

Health Technology

Health Technology

Finance

Health Technology

Health Technology

  1. Mercati
  2. Insiders
  3. Peter Greenleaf
-40%: Proroga eccezionale
g
:
:
ENTRA ORA